Calidi Biotherapeutics Files 8-K: Material Agreement & Equity Sales
Ticker: CLDWW · Form: 8-K · Filed: May 31, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $11.50, $0.60, $0.20, $2.1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-K
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics signed a big deal and sold some stock, filing an 8-K on May 31st.
AI Summary
Calidi Biotherapeutics, Inc. announced on May 31, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Calidi Biotherapeutics, including a new material agreement and equity transactions, which could impact its financial position and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40789 (identifier) — SEC File Number
- First Light Acquisition Group, Inc. (company) — Former company name
FAQ
What type of material definitive agreement did Calidi Biotherapeutics enter into?
The filing states that Calidi Biotherapeutics, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 31, 2024.
What is the SEC File Number for Calidi Biotherapeutics, Inc.?
The SEC File Number for Calidi Biotherapeutics, Inc. is 001-40789.
What was Calidi Biotherapeutics, Inc. formerly known as?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc.
What is the state of incorporation for Calidi Biotherapeutics, Inc.?
Calidi Biotherapeutics, Inc. is incorporated in Delaware.
Filing Stats: 1,519 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2024-05-31 17:00:37
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $11.50 — of common stock at an exercise price of $11.50 per share CLDIWS NYSE American LLC
- $0.60 — l 18, 2024 and had an exercise price of $0.60. Pursuant to the Inducement Letter, suc
- $0.20 — n stock, at a reduced exercise price of $0.20. The Series Warrants are exercisable fo
- $2.1 million — rrants are expected to be approximately $2.1 million in cash, prior to deducting placement a
- $0.30 — Warrants will have an exercise price of $0.30 per share, will be initially exercisabl
Filing Documents
- form8-k.htm (8-K) — 59KB
- ex4-1.htm (EX-4.1) — 129KB
- ex10-1.htm (EX-10.1) — 86KB
- ex99-1.htm (EX-99.1) — 11KB
- 0001493152-24-022229.txt ( ) — 556KB
- cldi-20240531.xsd (EX-101.SCH) — 4KB
- cldi-20240531_def.xml (EX-101.DEF) — 26KB
- cldi-20240531_lab.xml (EX-101.LAB) — 36KB
- cldi-20240531_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
01 Regulation
Item 7.01 Regulation FD Disclosure. On May 31, 2024, the Company issued a press release announcing the transactions described in Item 1.01 above. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information reported under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being "furnished" and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of New Warrant 10.1 Form of Inducement Letter 99.1 Press Release dated May 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Calidi Biotherapeutics, Inc. Dated: May 31, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer 3